Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Biotech company Enveda raised $311 million, valuing the firm at $2 billion. The company uses artificial intelligence to develop nature-derived drugs for clinical trials. Current projects include treatments for skin conditions and weight loss maintenance after GLP-1 therapy.
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
READ NEXT
More on the wire
AI TLDR
Iran's president criticized the United States during a speech at the U.N. General Assembly. The remarks followed a speech by President Donald Trump, who threatened to annihilate Iran. Both leaders utilized the same podium to address the international community.
AI TLDR
A man has filed a lawsuit alleging his First Amendment rights were violated when police raided his home. The action followed his posting of YouTube footage showing an officer speeding.
AI TLDR
Aleksandr and Nataliya Yeremeyev have filed a $10 million lawsuit against Salem Health and Dr. Stefani Sorensen. The parents allege the hospital forced them to transport their deceased baby home to Seattle.